Search for information about a product,
therapeutic area or event

Media, investors, advocacy organizations and others, please contact us here.

COMPOSE® Phase 1/2, dose-escalation Cohort 7 design: safety of pegtibatinase in children aged ≥5-<12 years with classical homocystinuria (HCU)

Page 1 / 1 100%
Loading...